PanGenetics "Experiment" Winding Down, CEO Kevin Johnson to Pursue Asset-Centric Model at Index Ventures

The Belgian biotech secured an exit for investors with last year's unusual front-end loaded NGF deal with Abbott, but lightning won't strike twice as its second program can't get through Phase I.